Regular Article
Characterization of Flavin-Containing Monooxygenase-5 (FMO5) Cloned from Human and Guinea-Pig: Evidence That the Unique Catalytic Properties of FMO5 Are Not Confined to the Rabbit Ortholog

https://doi.org/10.1006/abbi.1995.1163Get rights and content

Abstract

Several full-length clones encoding the human and guinea pig orthologs of flavin-containing monooxygenase 5 (FMO5) have been isolated from libraries constructed with hepatic mRNA. The clones were detected by hybridization with the cDNA encoding FMO5 expressed in rabbit. The human and guinea pig cDNAs encode for proteins of 533 amino acids that contain putative pyrophosphate binding domains characteristic of mammalian FMOs. The sequences derived for the human and guinea pig FMO5 proteins are 87% identical and are 85 and 82% identical, respectively, to the sequence of rabbit FMO5. As is the case with other FMOs, FMO5 in human and guinea pig is encoded by multiple transcripts. Rabbit FMO5 expressed in Escherichia coli was purified and used to elicit antibodies in goat. These antibodies detected FMO5 in samples from livers of adult humans, rabbits, and guinea pigs and fetal livers of humans. The human and guinea pig forms of FMO5 were expressed in E. coli and characterized. Neither enzyme effectively catalyzed the metabolism of methimazole, a general FMO substrate; however, both were active with n-octylamine. The responses of the human FMO5 and guinea pig FMO5 to detergent, ions and elevated temperature are all similar to the responses described for rabbit FMO5. These results indicate that the unique properties of FMO5 from rabbit are species-independent and that this form of the flavin-containing monooxygenase is not readily classified as a drug-metabolizing enzyme.

References (0)

Cited by (81)

  • Prenatal diagnosis of a familial 1q21.1-q21.2 microdeletion in a fetus with polydactyly of left foot on prenatal ultrasound

    2018, Taiwanese Journal of Obstetrics and Gynecology
    Citation Excerpt :

    PRKAB2 is expressed in skeletal and cardiac muscles [23]. FMO5 (OMIM 603957) encodes flavin-containing monooxygenase 5, which catalyzes the nucleophilic nitrogen, sulfur and phosphorus atoms and is expressed in human liver [25,26]. CHD1L (OMIM 613039) encodes chromodomain helicase DNA-binding protein 1-like, which plays a role in chromatin relaxation following DNA damage [27].

  • Monoamine Oxidases and Flavin-Containing Monooxygenases

    2018, Comprehensive Toxicology: Third Edition
  • The phenotype of a knockout mouse identifies flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing

    2015, Biochemical Pharmacology
    Citation Excerpt :

    FMO5 displays few characteristics of an enzyme involved in the detoxification of small foreign chemicals, with little or no activity towards classic FMO substrates, such as methimazole [12], trimethylamine [13] and benzydamine [14]. Knowledge of its substrates is limited [2,15,16]: it catalyzes the N-oxygenation of short-chain aliphatic primary amines such as N-octylamine [12] and the S-oxygenation of S-methyl-esonarimod, an active metabolite of the anti-rheumatic esonarimod [15,17]. The ability of FMO5 to catalyze a Baeyer–Villiger oxidation reaction was revealed in a study of an anti-cancer therapeutic [18].

  • PH dependence on functional activity of human and mouse flavin-containing monooxygenase 5

    2012, Biochemical Pharmacology
    Citation Excerpt :

    This is primarily due to a paucity of selective substrates. With typical FMO substrates such as methimazole or trimethylamine FMO5 does not show any functional activity [8], whereas it oxygenates long-chain phenothiazene analogs (i.e., 10-(N,N-dimethylaminooctyl)2-(trifluoromethyl)phenothiazene (8-DPT)) [8], n-octylamine [9,10], and S-methyl-esonarimod and its methoxy-analog [8,11]. A unique feature of mouse FMO5 (mFMO) is that when compared to the pH dependence of three other functional mFMOs (i.e., mFMO1, mFMO3, and mFMO4) and human FMO5 (hFMO5), it was found that the pH profile of mFMO5 differed significantly from that of all other FMO forms examined in the study [8].

  • Monoamine Oxidases and Flavin-Containing Monooxygenases

    2010, Comprehensive Toxicology, Second Edition
  • Phase I biotransformation reactions-flavin monooxygenase

    2007, xPharm: The Comprehensive Pharmacology Reference
View all citing articles on Scopus
View full text